Roivan­t's Vivek Ra­maswamy is clos­ing in on a $3B cash deal to sell con­trol of 5 Vants — plus — to Sum­it­o­mo ...

6 years ago
People
Deals

Pri­vate eq­ui­ty meets Chi­na biotech: PAG in­fus­es $540M to gain con­trol of Hisun's biosim­i­lar sub­sidiary

6 years ago
Deals
China

Glob­al Blood Ther­a­peu­tics buoyed by good news from FDA; Cigna to help cov­er pricey ther­a­pies

6 years ago
News Briefing

The 'mind-blow­ing' R&D re­nais­sance in psy­che­del­ic meds finds a home at Johns Hop­kins

6 years ago
R&D
Pharma

How much has the can­cer R&D fren­zy trans­lat­ed in­to drug ap­provals? A lot

6 years ago
R&D
FDA+

A bat­tered Zaf­gen seeks strate­gic op­tions, proph­esy­ing on­go­ing study will un­like­ly lift FDA hold on di­a­betes drug

6 years ago
R&D
FDA+

Strike three: Bris­tol-My­ers’ third I/O shot at glioblas­toma miss­es as Op­di­vo flops yet again on key end­point

6 years ago
R&D

Strug­gling poo-test­ing start­up uBio­me files for bank­rupt­cy, months af­ter FBI kicks off in­ves­ti­ga­tion

6 years ago
Startups
FDA+

Mallinck­rodt preps a pos­si­ble bank­rupt­cy amid a mael­strom of opi­oid claims — re­port

6 years ago
Pharma

The IFM team sets up a three-peat as No­var­tis funds cGAS/STING pro­gram — with $840M op­tion to buy

6 years ago
Deals
R&D

Ned Sharp­less in fi­nal run­ning for FDA com­mish with MD An­der­son ex­ec and Har­vard prof — re­ports

6 years ago
People
FDA+

The phar­ma in­dus­try's rep hits ab­solute. rock. bot­tom.

6 years ago
Pharma

Plot­ting clin­i­cal en­try, James Wilson's gene ther­a­py start­up brings in bil­lion­aire for $110M Se­ries B

6 years ago
Financing
Cell/Gene Tx

Bris­tol-My­ers is scout­ing new com­pa­ny star­tups; Ab­b­Vie and Idera team up to eval­u­ate com­bi­na­tion for HN­SCC

6 years ago
News Briefing

Ver­sant-backed pre­ci­sion on­col­o­gy start­up Re­pare Ther­a­peu­tics scores $82M+ in lat­est round

6 years ago
Financing
Startups

Ex-FDA chiefs, non-prof­its take Ned Sharp­less' cor­ner as clock ticks down on Trump's pick

6 years ago
R&D

Ko­re­an bio­phar­ma ex­ec­u­tive in­dict­ed for al­leged­ly con­duct­ing il­le­gal tri­als on com­pa­ny re­searchers

6 years ago
People
Pharma

Ver­tex buys the top spot on the list of the biggest pre­clin­i­cal M&A deals. Were they robbed or was it a steal?

6 years ago
Deals

Co-found­ed by Ver­sant, NEA in­vestors, new medtech VC firm kicks off in­au­gur­al fund with $225M boun­ty

6 years ago
Financing

Nkar­ta maps out clin­i­cal, man­u­fac­tur­ing plans for CAR-NK fol­low­ing $114M round led by Sam­sara

6 years ago
Financing
Startups

George Scan­gos heads back to Wall Street. And he’s bring­ing along some of the best con­nec­tions in biotech

6 years ago
Financing

US judge paves way for brand­ed and gener­ic opi­oid mak­ers to face land­mark Oc­to­ber tri­al

6 years ago
Pharma
FDA+

In the midst of a deal spree, Bay­er turns to vet­er­an J&J deal­mak­er Mar­i­anne De Backer to bring home the tech­nol­o­gy

6 years ago
People

Bel­lus hopes to fu­el up on IPO cash as it squares off with gi­ant Mer­ck on a ri­val drug

6 years ago
Financing
First page Previous page 902903904905906907908 Next page Last page
A service from the Financial Times